Evidence map›Paper›PMID 41726518›Full record

ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024

ProtoBERT-LoRA: Parameter-Efficient Prototypical Finetuning for Immunotherapy Study Identification.

Shijia Zhang, Xiyu Ding, Kai Ding, Jacob Zhang, Kevin Galinsky, Mengrui Wang, Ryan P Mayers, Zheyu Wang, Hadi Kharrazi

Abstract read
In one paragraph

Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shijia ZhangJohns Hopkins University School of Medicine, Baltimore, MD.
Xiyu DingJohns Hopkins University School of Medicine, Baltimore, MD.
Kai DingTakeda Pharmaceuticals, Cambridge, MA.
Jacob ZhangTakeda Pharmaceuticals, Cambridge, MA.
Kevin GalinskyTakeda Pharmaceuticals, Cambridge, MA.
Mengrui WangBoston University Graduate School of Arts and Science, Boston, MA.
Ryan P MayersUniversity of Maryland School of Medicine, Baltimore, MD.
Zheyu WangJohns Hopkins University School of Medicine, Baltimore, MD.
Hadi KharraziJohns Hopkins University School of Medicine, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying immune checkpoint inhibitor (ICI) studies in genomic repositories like Gene Expression Omnibus (GEO) is vital for cancer research yet remains challenging due to semantic ambiguity, extreme class imbalance, and limited labeled data in low-resource settings. We present ProtoBERT-LoRA, a hybrid framework that combines PubMedBERT with prototypical networks and Low-Rank Adaptation (LoRA) for efficient fine-tuning. The model enforces class-separable embeddings via episodic prototype training while preserving biomedical domain knowledge. Our dataset was divided as: Training (20 positive, 20 negative), Prototype Set (10 positive, 10 negative), Validation (20 positive, 200 negative), and Test (71 positive, 765 negative). Evaluated on test dataset, ProtoBERT-LoRA achieved F1-score of 0.624 (precision: 0.481, recall: 0.887), outperforming the rule-based system, machine learning baselines and finetuned PubMedBERT. Application to 44,287 unlabeled studies reduced manual review efforts by 82%. Ablation studies confirmed that combining prototypes with LoRA improved performance by 29% over stand-alone LoRA.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyNeoplasmsDatabases, GeneticHumansMachine LearningImmune Checkpoint Inhibitors

Identifiers

PMID41726518
PMCPMC12919447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.